No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Rapport Therapeutics to Present Data at the 2025 American Academy of Neurology Annual Meeting
Pleasing Signs As A Number Of Insiders Buy Rapport Therapeutics Stock
Insider Buying: Rapport Therapeutics Chief Financial Officer Bought US$101k Of Shares
Buy Rating Affirmed for Rapport Therapeutics Amid Promising RAP-219 Trials and Strong Financial Position
TD Cowen Sticks to Their Buy Rating for Rapport Therapeutics, Inc. (RAPP)
Rapport Therapeutics | 10-K: FY2024 Annual Report